nach oben

Erschienen in:

07.02.2024 | Original Research Article

Effect of Ticagrelor versus Clopidogrel on All-Cause and Cardiovascular Mortality in Acute Coronary Syndrome Patients with Hyperuricemia

verfasst von: Shanshan Nie, Yuhang Zhao, Zeying Feng, Chan Zou, Fangfang Ding, Liying Gong, Hongwei Lu, Yu Cao, Guoping Yang

Erschienen in: Clinical Drug Investigation | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

The relationship between hyperuricemia and mortality in patients with acute coronary syndrome (ACS) is considerably controversial. Additionally, the strategy of dual antiplatelet therapy (DAPT) has not been evaluated in patients with ACS with hyperuricemia. This study aims to evaluate the impact of hyperuricemia on the prognosis of ACS and explore the efficacy of ticagrelor compared with clopidogrel in patients with hyperuricemia.

Methods

The study enrolled 4319 patients divided into hyperuricemia (HUA, n = 1060) and normouricemia (NUA, n = 3259) groups. The inverse probability of treatment weighting (IPTW)-adjusted Cox regression analysis was used to evaluate the impact of ticagrelor versus clopidogrel on all-cause and cardiovascular mortality.

Results

Hyperuricemia significantly increased the risk of all-cause death compared with patients with NUA at 7 days [adjusted hazard ratio (HR): 4.292, 95% confidence interval (CI) 1.727–10.67]; P = 0.002), 14 days (adjusted HR: 2.871, 95% CI 1.326–6.219; P = 0.0074), 30 days (adjusted HR: 2.168, 95% CI 1.056–4.453; P = 0.035), 3 months (adjusted HR: 2.018, 95% CI 1.152–3.533; P = 0.0144) and 1 year (adjusted HR: 1.702, 95% CI 1.137–2.548; P = 0.009). No significant difference was found between ticagrelor and clopidogrel in 1-year all-cause mortality [7.0% versus 5.5%, adjusted HR: 1.114 (95% CI 0.609–2.037), P = 0.725] among patients with concomitant hyperuricemia.

Conclusion

Hyperuricemia was independently related to an increased risk of all-cause and cardiovascular death in patients with ACS undergoing PCI. At 1-year follow-up, there were no significant differences between ticagrelor and clopidogrel concerning all-cause and cardiovascular death in patients with hyperuricemia.

Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. Lancet. 2022;399(10332):1347–58. https://doi.org/10.1016/S0140-6736(21)02391-6.CrossRefPubMedPubMedCentral

Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327(7):662–75. https://doi.org/10.1001/jama.2022.0358.CrossRefPubMed

Virdis A, Masi S, Casiglia E, Tikhonoff V, Cicero A, Ungar A, et al. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension. 2020;75(2):302–8. https://doi.org/10.1161/HYPERTENSIONAHA.119.13643.CrossRefPubMed

Rodrigues BS, Alves M, Duarte GS, Costa J, Pinto FJ, Caldeira D. The impact of influenza vaccination in patients with cardiovascular disease: an overview of systematic reviews. Trends Cardiovasc Med. 2021;31(5):315–20. https://doi.org/10.1016/j.tcm.2020.06.003.CrossRefPubMed

Zhang M, Zhu X, Wu J, Huang Z, Zhao Z, Zhang X, et al. Prevalence of hyperuricemia among chinese adults: findings from two nationally representative cross-sectional surveys in 2015–16 and 2018–19. Front Immunol. 2021;12: 791983. https://doi.org/10.3389/fimmu.2021.791983.CrossRefPubMed

Gaubert M, Bardin T, Cohen-Solal A, Diévart F, Fauvel JP, Guieu R, et al. Hyperuricemia and hypertension, coronary artery disease, kidney disease: from concept to practice. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21114066.CrossRefPubMedPubMedCentral

Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16(1):15–24. https://doi.org/10.1093/eurjhf/hft132.CrossRefPubMed

Cheong E, Ryu S, Lee JY, Lee SH, Sung JW, Cho DS, et al. Association between serum uric acid and cardiovascular mortality and all-cause mortality: a cohort study. J Hypertens. 2017;35(Suppl 1):S3-09. https://doi.org/10.1097/HJH.0000000000001330.CrossRefPubMed

Landolfo M, Borghi C. Hyperuricaemia and vascular risk: the debate continues. Curr Opin Cardiol. 2019;34(4):399–405. https://doi.org/10.1097/HCO.0000000000000626.CrossRefPubMed

10.

Kamran H, Jneid H, Kayani WT, Virani SS, Levine GN, Nambi V, et al. Oral antiplatelet therapy after acute coronary syndrome: a review. JAMA. 2021;325(15):1545–55. https://doi.org/10.1001/jama.2021.0716.CrossRefPubMed

11.

Sibbing D, Aradi D, Alexopoulos D, Ten BJ, Bhatt DL, Bonello L, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12(16):1521–37. https://doi.org/10.1016/j.jcin.2019.03.034.CrossRefPubMed

12.

Tantry US, Navarese EP, Myat A, Gurbel PA. Selection of P2Y12 inhibitor in percutaneous coronary intervention and/or acute coronary syndrome. Prog Cardiovasc Dis. 2018;60(4–5):460–70. https://doi.org/10.1016/j.pcad.2018.01.003.CrossRefPubMed

13.

Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, et al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study. Circulation. 2013;127(6):673–80. https://doi.org/10.1161/CIRCULATIONAHA.112.124248.CrossRefPubMed

14.

Rodriguez F, Mahaffey KW. Management of patients with NSTE-ACS: a comparison of the recent AHA/ACC and ESC guidelines. J Am Coll Cardiol. 2016;68(3):313–21. https://doi.org/10.1016/j.jacc.2016.03.599.CrossRefPubMed

15.

Nie S, Chen K, Guo C, Pei Q, Zou C, Yao L, et al. Effect of CYP4F2 Polymorphisms on ticagrelor pharmacokinetics in healthy chinese volunteers. Front Pharmacol. 2021;12: 797278. https://doi.org/10.3389/fphar.2021.797278.CrossRefPubMed

16.

Butler K, Teng R. Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers. Clin Pharmacol Ther. 2012;91(2):264–71. https://doi.org/10.1038/clpt.2011.223.CrossRefPubMed

17.

Liu S, Wu X, Lopez AD, Wang L, Cai Y, Page A, et al. An integrated national mortality surveillance system for death registration and mortality surveillance. China Bull World Health Organ. 2016;94(1):46–57. https://doi.org/10.2471/BLT.15.153148.CrossRefPubMed

18.

Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656–64. https://doi.org/10.1093/aje/kwn164.CrossRefPubMedPubMedCentral

19.

Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7–13. https://doi.org/10.7326/0003-4819-131-1-199907060-00003.CrossRefPubMed

20.

Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148(1):131–9. https://doi.org/10.1016/s0021-9150(99)00214-2.CrossRefPubMed

21.

Panero F, Gruden G, Perotto M, Fornengo P, Barutta F, Greco E, et al. Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study. Atherosclerosis. 2012;221(1):183–8. https://doi.org/10.1016/j.atherosclerosis.2011.11.042.CrossRefPubMed

22.

Pagidipati NJ, Hess CN, Clare RM, Akerblom A, Tricoci P, Wojdyla D, et al. An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. Am Heart J. 2017;187:53–61. https://doi.org/10.1016/j.ahj.2017.02.023.CrossRefPubMedPubMedCentral

23.

Chen C, Dong J, Lv Q, Liu X, Zhang Q, Du X. Effect of asymptomatic hyperuricemia on mortality of elderly patients after elective percutaneous coronary intervention. Front Cardiovasc Med. 2022;9: 800414. https://doi.org/10.3389/fcvm.2022.800414.CrossRefPubMedPubMedCentral

24.

Ye Z, Lu H, Long M, Li L. Baseline serum uric acid levels are associated with all-cause mortality in acute coronary syndrome patients after percutaneous coronary intervention. Dis Markers. 2018;2018:9731374. https://doi.org/10.1155/2018/9731374.CrossRefPubMedPubMedCentral

25.

Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis. 2013;231(1):61–8. https://doi.org/10.1016/j.atherosclerosis.2013.08.023.CrossRefPubMed

26.

Li B, Chen L, Hu X, Tan T, Yang J, Bao W, Rong S. Association of serum uric acid with all-cause and cardiovascular mortality in diabetes. Diabetes Care. 2023;46(2):425–33. https://doi.org/10.2337/dc22-1339.CrossRefPubMed

27.

Gherghina ME, Peride I, Tiglis M, Neagu TP, Niculae A, Checherita IA. Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23063188.CrossRefPubMedPubMedCentral

28.

Han Y, Claessen BE, Chen SL, Chunguang Q, Zhou Y, Xu Y, et al. Ticagrelor with or without aspirin in chinese patients undergoing percutaneous coronary intervention: a TWILIGHT China substudy. Circ Cardiovasc Interv. 2022;15(4): e9495. https://doi.org/10.1161/CIRCINTERVENTIONS.120.009495.CrossRef

29.

Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO Randomized Clinical Trial. JAMA. 2020;323(23):2407–16. https://doi.org/10.1001/jama.2020.7580.CrossRefPubMedPubMedCentral

30.

Lee S, Wadowski PP, Hoberstorfer T, Weikert C, Pultar J, Kopp CW, et al. Decreased platelet inhibition by thienopyridines in hyperuricemia. Cardiovasc Drugs Ther. 2021;35(1):51–60. https://doi.org/10.1007/s10557-020-07058-x.CrossRefPubMed

31.

Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome—randomized, double-blind, phase III PHILO study. Circ J. 2015;79(11):2452–60. https://doi.org/10.1253/circj.CJ-15-0112.CrossRefPubMed

32.

Bryant CE, Rajai A, Webb NJA, Hogg RJ. Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria. Pediatr Nephrol. 2021;36(10):3211–9. https://doi.org/10.1007/s00467-021-05045-4.CrossRefPubMedPubMedCentral

33.

Ferreira JP, Zannad F, Kiernan MS, Konstam MA. High- versus low-dose losartan and uric acid: an analysis from HEAAL. J Cardiol. 2023;82(1):57–61. https://doi.org/10.1016/j.jjcc.2023.04.005.CrossRefPubMed

34.

Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, Touw D, Hoorn EJ, Nieuwdorp M, Kramer MMH, Joles JA, Bjornstad P, van Raalte DH. SGLT2 Inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clin J Am Soc Nephrol. 2022;17(5):663–71. https://doi.org/10.2215/CJN.11480821.CrossRefPubMedPubMedCentral

Titel: Effect of Ticagrelor versus Clopidogrel on All-Cause and Cardiovascular Mortality in Acute Coronary Syndrome Patients with Hyperuricemia
verfasst von: Shanshan Nie
Yuhang Zhao
Zeying Feng
Chan Zou
Fangfang Ding
Liying Gong
Hongwei Lu
Yu Cao
Guoping Yang
Publikationsdatum: 07.02.2024
Verlag: Springer International Publishing
Erschienen in: Clinical Drug Investigation / Ausgabe 3/2024
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI: https://doi.org/10.1007/s40261-024-01342-6

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Effect of Ticagrelor versus Clopidogrel on All-Cause and Cardiovascular Mortality in Acute Coronary Syndrome Patients with Hyperuricemia

Abstract

Background and Objective

Methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background and Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

Safety and Efficacy of Biologic Medications and Janus Kinase Inhibitors in Patients with Down Syndrome: A Retrospective Cohort Study

Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System

Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database

Safety of Intravenous Push Valproate Compared with Intravenous Piggyback at a Tertiary Academic Medical Center

Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)